Acute Myocardial Infarction and Acute Cerebral Infarction (AMIAC) Registry and Follow-up (AMIAC)

The Registry and Follow-up of Patients With Acute Myocardial Infarction or Acute Cerebral Infarction

A registry of consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction were conducted at the Guangdong General Hospital or the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Yue Bei People's Hospital, China, between January 2000 and December 2016. The adverse clinical outcomes, including all-cause mortality, were followed from the date of admission for acute myocardial infarction or acute cerebral infarction until study end (December 31, 2016). All-cause mortality, including the date of death, was identified from the electronic hospitalization data, phone follow-up, and confirmed by the household registration (HUKOU) system, a record of registration required by law in China. Baseline characteristics, including major treatment of acute myocardial infarction or acute cerebral infarction, estimated glomerular filtration rate (eGFR) and proteinuria, were collected. Demographic data were determined from the electronic hospitalization data and electronic hospital discharge records. All comorbid conditions were identified using International Statistical Classification of Diseases, Tenth Revision (ICD-10), coding algorithms applied to electronic physician claims and electronic hospital discharge records. Life style (smoking), treatment regimen at discharge, including angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), were determined from the electronic hospitalization data.

Study Overview

• Status: Unknown
• Conditions: Myocardial Infarction; Mortality; Chronic Kidney Diseases; Cerebral Infarction

• Study Type: Observational
• Enrollment (Anticipated): 30000

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510080
      • Guangdong General Hospital
    • Guangzhou, Guangdong, China, 510405
      • The First Affiliated Hospital of Guangzhou University of Chinese Medicine
    • Shaoguan, Guangdong, China, 512025
      • Yue Bei People's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

the consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction at the Guangdong General Hospital or the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Yue Bei People's Hospital, China, between January 2000 and December 2016.

Description

Inclusion Criteria:

• consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction

Exclusion Criteria:

• lacunar infarction

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
acute cerebral infarction; the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction
acute myocardial infarction; the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
all-cause mortality	all-cause mortality	follow up until the study end (May 2018,Anticipated)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
kidney outcome	ESRD or 50%eGFR decline	follow up until the study end (May 2018,Anticipated)

Collaborators and Investigators

• Sponsor: Guangdong Provincial People's Hospital
• Investigators: Study Director: Liming Yao, M.D., Guangdong Provincial People's Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 3, 2000
• Primary Completion (Anticipated): May 1, 2018
• Study Completion (Anticipated): May 1, 2018

Study Registration Dates

• First Submitted: May 18, 2017
• First Submitted That Met QC Criteria: May 24, 2017
• First Posted (Actual): May 25, 2017

Study Record Updates

• Last Update Posted (Actual): May 25, 2017
• Last Update Submitted That Met QC Criteria: May 24, 2017
• Last Verified: May 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Ischemia; Pathologic Processes; Necrosis; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Urologic Diseases; Renal Insufficiency; Brain Ischemia; Stroke; Brain Infarction; Myocardial Infarction; Infarction; Kidney Diseases; Renal Insufficiency, Chronic; Cerebral Infarction
• Other Study ID Numbers: 20170309

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No